Hiv drug sits at the center of this dementia and brain health question.
The HIV drug making headlines for its role in prevention rather than treatment is lenacapavir, sold under the brand name Yeztugo. Approved by the FDA on June 18, 2025, it is the first and only HIV prevention option that requires just two injections per year — one every six months. In clinical trials, lenacapavir achieved something remarkable: zero HIV infections among cisgender women in sub-Saharan Africa and a 96% reduction in HIV risk in a broader global study. For the millions of people at risk of HIV exposure worldwide, a twice-yearly shot represents a dramatic shift from the daily pill regimen that has defined pre-exposure prophylaxis, or PrEP, for over a decade. This matters beyond infectious disease circles.
For older adults managing multiple medications, for caregivers juggling complex care routines, and for anyone tracking the intersection of public health and medical innovation, the arrival of long-acting PrEP illustrates how drug delivery is evolving across medicine. The same principle — reducing the burden of daily adherence — drives research in Alzheimer’s therapeutics, cardiovascular care, and chronic disease management. This article covers what PrEP is and how it works, the breakthrough behind lenacapavir, the sharp debate over its pricing, who can access it, the racial disparities that persist in PrEP coverage, and what the pipeline holds for the next generation of HIV prevention tools. The story of PrEP’s evolution from a once-daily pill to a twice-yearly injection is, at its core, a story about removing barriers. And the barriers that remain — cost, equity, awareness — are ones worth understanding regardless of your connection to HIV.
Table of Contents
- How Does an HIV Drug Prevent Transmission Before Exposure Actually Occurs?
- What Makes Lenacapavir Different From Every Other PrEP Drug
- The Pricing Controversy That Threatens to Undermine a Medical Breakthrough
- Who Can Get PrEP and What Does Insurance Actually Cover
- Racial Disparities in PrEP Access Remain a Serious Problem
- What the Pipeline Holds for HIV Prevention Beyond 2026
- Why This Matters for Brain Health and Aging
- Conclusion
- Frequently Asked Questions
How Does an HIV Drug Prevent Transmission Before Exposure Actually Occurs?
Pre-exposure prophylaxis works by maintaining protective levels of antiretroviral medication in the body before any potential contact with HIV. When the virus enters the body through sex or injection drug use, PrEP drugs block it from establishing a permanent infection. According to the CDC, daily oral PrEP reduces the risk of getting HIV from sex by approximately 99% and from injection drug use by at least 74%. The concept is analogous to how certain medications can prevent malaria in travelers — you take the drug before exposure, not after. The FDA has approved four PrEP options as of 2026. Truvada, a daily oral pill approved in 2012, was the first. Descovy followed in 2019 as another daily pill with a slightly different formulation.
Apretude, approved in 2021, moved beyond pills entirely as a long-acting injectable given every two months. Then came Yeztugo, the lenacapavir-based injection approved in June 2025, which only needs to be administered twice a year. Each successive option has aimed to reduce the frequency of dosing, because adherence to daily pills is one of the biggest challenges in real-world PrEP effectiveness. The difference between taking a pill every morning and getting an injection twice a year is not trivial. Studies have consistently shown that people who miss doses of oral PrEP lose significant protection. A person who takes daily Truvada perfectly is well-protected, but a person who takes it four days a week may have substantially lower protection. Long-acting injectables like lenacapavir sidestep this problem almost entirely — once the injection is administered, the drug maintains therapeutic levels in the body for six months without any action required from the patient.
What Makes Lenacapavir Different From Every Other PrEP Drug
Lenacapavir is a capsid inhibitor, meaning it works by a completely different mechanism than all other PrEP medications. While drugs like Truvada and Descovy target specific enzymes HIV needs to replicate, lenacapavir goes after the virus’s protein shell — called the capsid — and disrupts it at multiple stages of the viral lifecycle. This multi-point attack is part of why the drug is so effective and why resistance is expected to develop more slowly. The dosing regimen involves a brief oral loading phase at the first visit — two pills on day one and two pills on day two — followed by subcutaneous injections in the abdomen every six months. The PURPOSE 1 trial, conducted among cisgender women in sub-Saharan Africa, recorded zero HIV infections among participants receiving lenacapavir. The PURPOSE 2 trial, which included a broader and more diverse population, found only 2 infections out of 2,180 participants receiving lenacapavir, compared to 9 infections among 1,087 people on daily oral Truvada.
that translates to an 89% greater effectiveness than the gold-standard daily pill. However, lenacapavir is not without limitations. Because it is delivered by injection, it requires a healthcare visit every six months — which, while far less burdensome than daily pills, still depends on access to a provider trained in its administration. People in rural areas or those without stable healthcare relationships may find this challenging. And if someone has an adverse reaction to the drug, it cannot simply be stopped the way a daily pill can — the medication remains in the body for months after injection. The WHO endorsed lenacapavir for HIV prevention in 2025, expanding the global toolkit, but acknowledged that implementation will require significant healthcare infrastructure investment in many regions.
The Pricing Controversy That Threatens to Undermine a Medical Breakthrough
Yeztugo’s U.S. list price is $28,218 per year — $14,109 per injection, administered twice annually. This was actually a reduction from the roughly $42,000 per year the drug costs when used as an HIV treatment rather than for prevention. By comparison, Apretude, the every-two-months injectable, runs approximately $24,000 per year. These are staggering numbers for a preventive medication, particularly one that public health experts say should be reaching millions of at-risk people. The pricing becomes even more striking when you consider the manufacturing economics.
Researchers have estimated that generic versions of lenacapavir could be produced for as little as $25 per person per year — roughly one-thousandth of the U.S. list price. The Gates Foundation and Unitaid have secured agreements to make generic lenacapavir available for $40 per patient per year in 120 low-income countries, but those agreements do not take effect until 2027, and they do not apply to the United States. For Americans without insurance or with high-deductible plans, the gap between what the drug costs to make and what they are asked to pay is enormous. This tension between innovation and access is not unique to HIV prevention. It mirrors debates around Alzheimer’s drugs like lecanemab, where breakthrough treatments carry price tags that strain both public programs and private budgets. The question of how to price drugs that could prevent disease at a population level — versus treating it after the fact — remains one of the most consequential policy discussions in American healthcare.
Who Can Get PrEP and What Does Insurance Actually Cover
The good news on the access front is that federal policy has moved to eliminate most out-of-pocket costs for PrEP. The U.S. Preventive Services Task Force gives PrEP a Grade A recommendation, which means most private insurers are required to cover it with no cost-sharing under the Affordable Care Act. Medicare now covers PrEP under Part B with no cost-sharing as well, including the medications themselves, administration fees, counseling, and necessary screenings like kidney function tests and HIV status checks. In practice, however, coverage does not always equal access. A person needs to know PrEP exists, have a provider willing to prescribe it, get to a clinic for injections or regular follow-ups, and navigate insurance paperwork.
For older adults who may be newly single after the death of a spouse, or for people re-entering the dating world after a long-term relationship, the idea of asking a doctor about HIV prevention can feel uncomfortable or even irrelevant — despite the fact that HIV diagnoses among adults over 50 have been rising. The tradeoff between oral and injectable PrEP extends beyond efficacy. Daily pills like Truvada are available as generics for a fraction of the cost of branded injectables, and they can be prescribed by any provider and picked up at any pharmacy. Apretude requires a clinic visit every two months. Lenacapavir requires visits only twice a year but at a far higher price point. For someone with stable insurance and good healthcare access, the twice-yearly injection may be ideal. For someone without those advantages, generic daily pills may remain the most practical option for years to come.
Racial Disparities in PrEP Access Remain a Serious Problem
Despite rising PrEP use — 591,475 people were using PrEP in the U.S. as of 2024, a 17% increase from 2023 — the people who need it most are often the least likely to have it. Black Americans represent just 14% of PrEP users but account for 42% of new HIV diagnoses. Hispanic and Latinx individuals make up 17% of PrEP users but 27% of new diagnoses. These gaps are not explained by differences in risk behavior. They reflect systemic disparities in healthcare access, provider awareness, medical trust, and insurance coverage. The geographic data tells a similar story.
States with the highest PrEP coverage saw a 38% decrease in new HIV diagnoses over the past decade. States with the lowest PrEP coverage saw a 27% increase. With more than 39,000 new HIV diagnoses in the U.S. in 2023 — over 80% of them among men — the places and populations where PrEP penetration is lowest are the same ones where the epidemic continues to grow. New tools like lenacapavir will not fix these disparities on their own. A twice-yearly injection is only an improvement if the people who would benefit from it can actually get to a clinic, afford the drug, and trust the system enough to walk through the door. Public health campaigns that focus only on drug approval without addressing the structural barriers to uptake risk widening the very gaps they aim to close. This is a lesson that applies across chronic disease management — from diabetes to dementia screening — and one that policymakers and healthcare systems have been slow to internalize.
What the Pipeline Holds for HIV Prevention Beyond 2026
The next frontier is even less frequent dosing. Merck’s MK-8527 is a once-monthly oral PrEP pill currently in Phase 3 clinical trials, having demonstrated the ability to maintain protective drug levels for 28 or more days. For people who prefer pills over injections but struggle with daily adherence, a monthly option could fill a significant gap.
Meanwhile, the PURPOSE 365 trial is studying whether lenacapavir can be effective as a once-yearly injection for PrEP. If successful, HIV prevention could become an annual healthcare event — something you do at the same visit where you get a flu shot or a routine blood panel. The trajectory from daily pills in 2012 to potentially annual injections within the next few years represents one of the most compressed timelines of progress in preventive medicine.
Why This Matters for Brain Health and Aging
HIV and brain health are more closely linked than many people realize. Untreated HIV can lead to HIV-associated neurocognitive disorders, a spectrum of conditions that includes memory problems, difficulty concentrating, and in severe cases, a form of dementia. Even with effective antiretroviral treatment, chronic inflammation from long-term HIV infection has been associated with accelerated cognitive aging. Preventing HIV infection in the first place is, in a very direct sense, a form of brain health protection.
For older adults and their caregivers, the broader lesson from PrEP’s evolution is one of empowerment through prevention. The same philosophy that drives dementia risk reduction — managing cardiovascular health, staying socially engaged, addressing hearing loss, controlling diabetes — applies here. Prevention is almost always more effective, less costly, and less burdensome than treatment. The development of a twice-yearly injection that can virtually eliminate the risk of HIV infection is a powerful example of what preventive medicine can accomplish when the science, the funding, and the political will align.
Conclusion
The approval of lenacapavir as Yeztugo marks a genuine turning point in HIV prevention. A twice-yearly injection that achieved zero infections in one major trial and a 96% risk reduction in another represents the kind of advance that can reshape public health — if it reaches the people who need it. The progression from daily Truvada to bimonthly Apretude to twice-yearly Yeztugo, with monthly pills and annual injections on the horizon, shows a field that is relentlessly focused on making prevention easier and more reliable. But the challenges are real.
A $28,218 annual price tag in a country where the drug could be manufactured for $25 raises hard questions about who benefits from medical innovation. Persistent racial and geographic disparities in PrEP access mean that the communities bearing the heaviest burden of HIV are the last to receive its most effective tools. For readers of this site, the connections to brain health, medication adherence in aging populations, and the value of prevention over treatment are direct and relevant. Staying informed about advances like PrEP — and advocating for equitable access to them — is part of the broader work of protecting health across the lifespan.
Frequently Asked Questions
What is PrEP and how effective is it at preventing HIV?
PrEP, or pre-exposure prophylaxis, uses antiretroviral medications taken before potential HIV exposure to prevent infection. Daily oral PrEP reduces the risk of getting HIV from sex by approximately 99% and from injection drug use by at least 74%, according to the CDC. The newest option, lenacapavir (Yeztugo), is a twice-yearly injection that showed a 96% reduction in HIV risk in clinical trials.
How does lenacapavir (Yeztugo) differ from other PrEP medications?
Lenacapavir is a capsid inhibitor that targets HIV’s protein shell at multiple stages of its lifecycle, a completely different mechanism from other PrEP drugs. It is administered as two subcutaneous injections per year after an initial oral loading dose, making it the least frequent dosing option available. In the PURPOSE 1 trial, it achieved zero HIV infections among participants.
Does insurance cover PrEP medications?
Yes, for most people. The USPSTF gives PrEP a Grade A recommendation, which requires most private insurers to cover it with no out-of-pocket costs. Medicare covers PrEP under Part B with no cost-sharing, including the drug, administration, counseling, and required lab screenings.
Why is there concern about lenacapavir’s pricing?
Yeztugo’s U.S. list price is $28,218 per year, while researchers estimate generic versions could be manufactured for as little as $25 per person per year. Agreements for low-income countries will bring the price to $40 per patient annually starting in 2027, but no such pricing exists for U.S. patients without insurance coverage.
Can older adults benefit from PrEP?
Yes. HIV diagnoses among adults over 50 have been rising, and anyone at risk of HIV exposure through sex or injection drug use can benefit from PrEP regardless of age. Preventing HIV also protects brain health, as untreated HIV can lead to neurocognitive disorders and chronic infection has been linked to accelerated cognitive aging.
What new PrEP options are in development?
Merck’s MK-8527 is a once-monthly oral PrEP pill in Phase 3 trials, offering an option for people who prefer pills but struggle with daily adherence. The PURPOSE 365 trial is investigating whether lenacapavir could work as a once-yearly injection, which would make HIV prevention an annual event.
You Might Also Like
- Why This Gut Drug Is Now Being Tried for Parkinson’s Disease
- Why Some Antibiotics Need to Be Taken Standing Up to Prevent Injury
- Why Doctors Are Testing a Diabetes Drug for Kidney Stone Prevention
For more, see NIH MedlinePlus — dementia.
